A viable, effective, widely-distributed vaccine for Covid-19 may soon be a reality. At best, it holds the potential to eradicate this pandemic and usher in a return to some semblance of normalcy.
Managers who have spent the past nine months optimizing their “remote” teams are now facing a new set of uncertainties. Will this vaccine end the pandemic? Will business-as-usual resume? Is a “return” to normal even a worthy goal? Should offices reopen? Not just from a health perspective, but more generally, are offices actually a good investment? If so, what should a company’s vaccine policy be?
